Literature DB >> 31291018

Emerging Treatment Targets for Migraine and Other Headaches.

Zachariah Bertels1, Amynah Amir Ali Pradhan1.   

Abstract

Migraine is a complex disorder that is characterized by an assortment of neurological and systemic effects. While headache is the most prominent feature of migraine, a host of symptoms affecting many physiological functions are also observed before, during, and after an attack. Furthermore, migraineurs are heterogeneous and have a wide range of responses to migraine therapies. The recent approval of calcitonin gene-related-peptide based therapies has opened up the treatment of migraine and generated a renewed interest in migraine research and discovery. Ongoing advances in migraine research have identified a number of other promising therapeutic targets for this disorder. In this review, we highlight emergent treatments within the following biological systems: pituitary adenylate cyclase activating peptdie, 2 non-mu opioid receptors that have low abuse liability - the delta and kappa opioid receptors, orexin, and nitric oxide-based therapies. Multiple mechanisms have been identified in the induction and maintenance of migraine symptoms; and this divergent set of targets have highly distinct biological effects. Increasing the mechanistic diversity of the migraine tool box will lead to more treatment options and better patient care.
© 2019 American Headache Society.

Entities:  

Keywords:  delta opioid receptor; kappa opioid receptor; nitric oxide synthase; orexin; pituitary adenylate cyclase activating peptide; soluble guanylyl cyclase

Year:  2019        PMID: 31291018      PMCID: PMC6986366          DOI: 10.1111/head.13585

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  141 in total

Review 1.  Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1.

Authors:  Anthony J Harmar; Jan Fahrenkrug; Illana Gozes; Marc Laburthe; Victor May; Joseph R Pisegna; David Vaudry; Hubert Vaudry; James A Waschek; Sami I Said
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

2.  Evidence for orexinergic mechanisms in migraine.

Authors:  Jan Hoffmann; Weera Supronsinchai; Simon Akerman; Anna P Andreou; Christopher J Winrow; John Renger; Richard Hargreaves; Peter J Goadsby
Journal:  Neurobiol Dis       Date:  2014-11-04       Impact factor: 5.996

3.  Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition.

Authors: 
Journal:  Cephalalgia       Date:  2018-01       Impact factor: 6.292

4.  Use of opioid medications for chronic noncancer pain syndromes in primary care.

Authors:  M Carrington Reid; Laura L Engles-Horton; MaryAnn B Weber; Robert D Kerns; Elizabeth L Rogers; Patrick G O'Connor
Journal:  J Gen Intern Med       Date:  2002-03       Impact factor: 5.128

Review 5.  Cortical spreading depression and migraine.

Authors:  Andrew C Charles; Serapio M Baca
Journal:  Nat Rev Neurol       Date:  2013-09-17       Impact factor: 42.937

6.  PACAP-deficient mice show attenuated corticosterone secretion and fail to develop depressive behavior during chronic social defeat stress.

Authors:  Michael L Lehmann; Tomris Mustafa; Adrian M Eiden; Miles Herkenham; Lee E Eiden
Journal:  Psychoneuroendocrinology       Date:  2012-10-11       Impact factor: 4.905

7.  Delta-opioid receptors as targets for migraine therapy.

Authors:  Andrew Charles; Amynah A Pradhan
Journal:  Curr Opin Neurol       Date:  2016-06       Impact factor: 5.710

Review 8.  CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications.

Authors:  David W Dodick
Journal:  Cephalalgia       Date:  2019-01-19       Impact factor: 6.292

Review 9.  Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

Authors: 
Journal:  Lancet       Date:  2015-06-07       Impact factor: 202.731

Review 10.  Discovery of the nitric oxide signaling pathway and targets for drug development.

Authors:  Nathan S Bryan; Ka Bian; Ferid Murad
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01
View more
  5 in total

1.  A non-convulsant delta-opioid receptor agonist, KNT-127, reduces cortical spreading depression and nitroglycerin-induced allodynia.

Authors:  Zachariah Bertels; Wiktor D Witkowski; Sarah Asif; Kendra Siegersma; Richard M van Rijn; Amynah A Pradhan
Journal:  Headache       Date:  2020-12-16       Impact factor: 5.887

2.  Delta opioid receptor regulation of calcitonin gene-related peptide dynamics in the trigeminal complex.

Authors:  Laura S Moye; Kendra Siegersma; Isaac Dripps; Wiktor Witkowski; Elizaveta Mangutov; Dong Wang; Grégory Scherrer; Amynah A Pradhan
Journal:  Pain       Date:  2021-08-01       Impact factor: 7.926

3.  A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention.

Authors:  Messoud Ashina; David Doležil; Jo H Bonner; Lifen Zhou; Jan Klatt; Hernan Picard; Daniel D Mikol
Journal:  Cephalalgia       Date:  2020-11-24       Impact factor: 6.292

Review 4.  New Oral Drugs for Migraine.

Authors:  Nazia Karsan; Peter J Goadsby
Journal:  CNS Drugs       Date:  2022-08-29       Impact factor: 6.497

5.  A Phase I, Randomized, Single‑Blind, Placebo‑Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Oral TRV250, a G Protein-Selective Delta Receptor Agonist, in Healthy Subjects.

Authors:  Michael J Fossler; Virginia Schmith; Stephen A Greene; Lauren Lohmer; Michael S Kramer; Kelly Arscott; Ian E James; Mark A Demitrack
Journal:  CNS Drugs       Date:  2020-08       Impact factor: 5.749

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.